|Day Low/High||91.08 / 95.14|
|52 Wk Low/High||55.00 / 133.62|
Incyte Corporation (Nasdaq: INCY) today announced that its first-in-class JAK1/JAK2 inhibitor, Jakafi ® (ruxolitinib), has been included as a recommended treatment in the latest National Comprehensive Cancer...
UnitedHealth becomes the second major healthcare provider to scratch the insulin product from its 2017 medicines roster.
Incyte Corporation calls for increased awareness and support for those living with myeloproliferative neoplasms (MPNs) today, MPN Awareness Day, and throughout September, Blood Cancer Awareness Month.
Cramer says he liked Yelp's quarter and is staying away from Cheniere Energy.
Cramer finds the good and the bad in the continued oil glut.
Incyte Corporation (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of September: Morgan Stanley Global Healthcare Conference on Wednesday, September...
Incyte Corporation (Nasdaq:INCY) today announced it has been ranked 4th on Forbes magazine's 2016 list of the World's Most Innovative Companies.
Pfizer (PFE) has agreed to acquire Medivation (MDVN) for $14 billion, fueling speculation of a future deal with Incyte (INCY).
Barclays increased its price target to $100 on Incyte (INCY) stock this morning.
The company's share price despite reporting better-than-expected earnings and revenue and
Trade-Ideas LLC identified Incyte (INCY) as a "roof leaker" (crossing below the 200-day simple moving average on higher than normal relative volume) candidate
Incyte Corporation (Nasdaq: INCY) today reports 2016 second-quarter financial results, including strong revenue growth driven by increased sales of Jakafi ® (ruxolitinib) in the U.
Stocks with insider trader activity include CFFI, KERX and INCY
The company also could look to acquire a smaller biotech company, though likely not Medivation.
The most recent short interest data has been released for the 07/15/2016 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.
TheStreet highlights 3 stocks pushing the health services industry lower today.
Incyte Corporation (Nasdaq:INCY) announces that updated data from the Phase 1 portion of the ECHO-202/KEYNOTE-037 trial has been accepted for a poster discussion at the European Society for Medical Oncology (ESMO) Annual...
Incyte Corporation (Nasdaq: INCY) announced today that it has scheduled its second quarter 2016 financial results conference call and webcast for 10:00 a.
TheStreet highlights 3 stocks pushing the health care sector lower today.
TheStreet's Adam Feuerstein answers reader questions about biotech stocks.
Besides Sanofi, Biogen is the next most likely to complete a sizable transaction in the next 12 months, according to Credit Suisse analysts.
Incyte Corporation (Nasdaq: INCY) today announced that the U.S.
Incyte Corporation (Nasdaq: INCY) today announced that the first patient has been treated in the ECHO-301 study—a Phase 3 trial evaluating epacadostat, Incyte's investigational, highly potent and selective oral IDO1...
Incyte Corporation (Nasdaq: INCY) today announced new 28-week data from the Phase 3 RESPONSE-2 study of Jakafi ® (ruxolitinib).
Incyte Corporation (Nasdaq:INCY) today announces five-year data from the Phase 3 COMFORT-I study evaluating the long-term safety and efficacy of Jakafi ® (ruxolitinib) in patients with intermediate-2 or high-risk...
Incyte Corporation (Nasdaq: INCY) and Moffitt Cancer Center today announced that they have entered into a research support and collaboration agreement, whereby Incyte has agreed to provide funding to conduct three new...
Incyte Corporation (Nasdaq: INCY), a biopharmaceutical company, today announced the launch of the Incyte Charitable Giving Foundation, which will provide charitable donations to publicly-funded 501(c)(3) tax-exempt...
TheStreet highlights 3 stocks pushing the health care sector higher today.